Summary
Blueprint Medicines Corp (Blueprint Medicines), formerly Hoyle Pharmaceuticals Inc, is a drug discovery company that develops drugs for the treatment of cancers and rare diseases. The company discovers and develops selective kinase inhibitors for genomically defined cancer subsets. Its pipeline products include BLU-554, used in advanced hepatocellular carcinoma; avapritinib, used in the treatment for unresectable, treatment-resistant gastrointestinal stromal tumors and advanced systemic mastocytosis; and BLU-667, for ret-mutations, fusions, and predicted resistant mutants. Its preclinical product candidate BLU-782 is intended for ALK2 mutations in fibrodysplasia ossificans progressiva. The company also discovers product candidates for kinase targets and immunokinase targets. The company operates through genomic and cancer research institutions located in the US. Blueprint Medicines is headquartered in Cambridge, Massachusetts, the US.

Blueprint Medicines Corp Key Recent Developments

Feb 26,2019: Blueprint Medicines reports fourth quarter and full year 2018 financial results
Jan 04,2019: Blueprint medicines announces “2020 blueprint” global business strategy and outlines key corporate goals
Oct 30,2018: Blueprint Medicines reports third quarter 2018 financial results
Oct 29,2018: Blueprint Medicines strengthens leadership with the appointments of Christina Rossi as chief commercial officer and Paul Beresford as general manager, international
Oct 01,2018: Blueprint Medicines Presents Foundational Preclinical Data Supporting the Development of BLU-782 a Highly Selective ALK2 Inhibitor for the Treatment of Patients with Fibrodysplasia Ossificans Progressiva

This comprehensive SWOT profile of Blueprint Medicines Corp provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Blueprint Medicines Corp including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.